MARINUS PHARMACEUTICALS INC logo

MRNS

MARINUS PHARMACEUTICALS INC

$4.63

Earnings Summary

Revenue
$0Mn
Net Profits
$-15.41Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

MARINUS PHARMACEUTICALS INC’s revenue jumped NaN% since last year same period to $0Mn in the Q4 2019. On a quarterly growth basis, MARINUS PHARMACEUTICALS INC has generated NaN% jump in its revenue since last 3-months.

Net Profits:

MARINUS PHARMACEUTICALS INC’s net profit fell -52.38% since last year same period to $-15.41Mn in the Q4 2019. On a quarterly growth basis, MARINUS PHARMACEUTICALS INC has generated -11.61% fall in its net profits since last 3-months.

Net Profit Margins:

MARINUS PHARMACEUTICALS INC’s net profit margin jumped NaN% since last year same period to -Inf% in the Q4 2019. On a quarterly growth basis, MARINUS PHARMACEUTICALS INC has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the MARINUS PHARMACEUTICALS INC post its latest quarter earnings

EPS Estimate Current Quarter
-1.05
EPS Estimate Current Year
-1.05

Highlights

EPS Estimate Current Quarter:

MARINUS PHARMACEUTICALS INC’s earning per share (EPS) estimates for the current quarter stand at -1.05 - a -6.21% fall from last quarter’s estimates.

EPS Estimate Current Year:

MARINUS PHARMACEUTICALS INC’s earning per share (EPS) estimates for the current year stand at -1.05.

Key Ratios

Key ratios of the MARINUS PHARMACEUTICALS INC post its Q2 2022 earnings

Earning Per Share (EPS)
-1.06
Return on Assets (ROA)
-0.4
Return on Equity (ROE)
-0.17

Highlights

Earning Per Share (EPS):

MARINUS PHARMACEUTICALS INC’s earning per share (EPS) fell -63.08% since last year same period to -1.06 in the Q2 2022. This indicates that the MARINUS PHARMACEUTICALS INC has generated -63.08% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. MARINUS PHARMACEUTICALS INC’s return on assets (ROA) stands at -0.4.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. MARINUS PHARMACEUTICALS INC’s return on equity (ROE) stands at -0.17.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.84
-0.52
38.02%
2022-08-11
-0.91
-1.06
-16.48%

Company Information

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety potential. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 3 trial in refractory status epilepticus, Phase 2 trial in tuberous sclerosis complex and a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy.

Organisation
MARINUS PHARMACEUTICALS INC
Headquarters
5 Radnor Corporate Center, Radnor, PA, United States, 19087
Employees
113
Industry
Health Technology

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*